Inhaled therapy can only work when medicine reaches where it needs to go.
For too many patients, this is where treatment breaks down. Medication is wasted before it reaches the lungs. Devices rely on timing, technique and breathing strength. Mesh systems can clog.
Particle size can vary. Patients with compromised breathing are often expected to adapt to systems that were not built around their reality.
MISTI® is being developed to change the delivery equation.
Using high frequency acoustic energy, breath actuation and connected treatment visibility, MISTI® is designed to generate a fine, controlled aerosol without relying on a traditional mesh.
MISTI® is built around a simple principle: aerosol delivery should respond to the patient’s breath.
The system brings together a breath actuated transducer, pre filled liquid cartridge, wearable mask
and connected digital layer to support more reliable pulmonary drug delivery.
The system senses when the patient begins to breathe in.
The core transducer uses high frequency acoustic energy to generate a fine aerosol.
Medicine moves through a hands free interface designed to reduce coordination demands.
The system records breath events, actuation timing, device use and delivery related information.
Connected insights may support adherence tracking, remote monitoring and clinical review.
Many nebulisers rely on mesh technology to generate aerosol. While widely used, mesh based systems can create known limitations when drug flow is restricted, particles vary, or formulations are not suited to the device.
MISTI® uses high frequency acoustic energy instead of forcing liquid through a mesh.
This supports a different approach to pulmonary delivery. One designed to reduce clogging risk, support more consistent aerosol generation and create a stronger pathway for sensitive or complex formulations.
For standard respiratory medicines, this may support more reliable delivery. For advanced formulations, it may help address one of the core barriers to inhaled therapeutic development: getting medicine into the lungs without compromising the medicine itself.
MISTI® combines aerosol science, breath actuation and connected technology to support a more controlled delivery experience.
Less risk of clogging and underdosing
The acoustofluidic system generates aerosol without relying on a clog prone mesh, supporting more consistent flow and reducing delivery disruption linked to blockage.
Delivery aligned with the patient’s inhale
Medicine is released in response to inhalation, helping align dose delivery with the patient’s breathing pattern.
Particle control for targeted lung delivery
Particle size influences where medicine travels in the respiratory system. MISTI® is designed to support controlled micron sized aerosol particles suitable for pulmonary delivery.
A clearer view of what actually happened
MISTI® can support device use logs, breath actuation data, dose consistency information and connected adherence pathways.
Usability for real patient behaviour
The wearable mask and breath actuated format are designed to reduce reliance on perfect technique, making inhaled therapy more practical for patients who may struggle with traditional devices.
The next era of medicine is being shaped by biologics, RNA therapeutics, gene therapies
and other complex formulations. But these therapies can be sensitive to heat, shear force,
formulation conditions and delivery method. That creates a major challenge for inhaled delivery.
Early technical work has shown promising results for biologic integrity, including in vitro work using lipid nanoparticle mRNA constructs.
For pharmaceutical partners, the opportunity is significant.
A more controlled pulmonary delivery pathway may help reduce delivery uncertainty, support formulation conscious aerosolisation, improve delivery testing and create new possibilities for hard to deliver therapies.
The ambition is bigger than improving today’s inhaled medicines.
MISTI® is being built to help make future medicines easier to deliver through the lungs.
One of the biggest challenges in respiratory care is knowing what actually happened during treatment.
MISTI® is designed to capture the signals that make delivery visible, including breath detection, actuation timing, device use, dose consistency and delivery related performance data.
This connected layer may support adherence tracking, remote monitoring, clinical follow up and better treatment decisions.
When care teams can see more, they can respond earlier.
MedMISTI™ is the first real world application of MISTI’s pulmonary delivery technology.
It gives the platform a focused starting point: respiratory care patients whose treatment success depends on usability, timing and consistency.
MedMISTI™ has been designed for patients who need inhaled therapy to be more usable and better aligned to real patient behaviour. That includes children, elderly patients, people living with asthma or COPD, neurodiverse patients, and people who may struggle with traditional inhalers, spacers or nebulisers.
The wearable, breath actuated format is intended to reduce coordination demands and make treatment feel less intimidating.
For healthcare providers, MedMISTI™ may create a clearer view of treatment use. For caregivers, it may reduce uncertainty around whether treatment was completed properly. For patients, it may make respiratory care feel more manageable.
That is where the technology matters most: not in the device alone, but in the moment it helps someone breathe easier.
MISTI® is built on more than a decade of research and development across acoustofluidics, aerosol science,
respiratory medicine and medical device design. The technology is grounded in peer reviewed work relating to
surface acoustic wave nebulisation and pulmonary delivery. This foundation is supported by research,
engineering and commercialisation ecosystems connected to respected institutions and medtech programmes.
Key credibility signals include:
✓ More than 10 years of research and development
✓ Acoustofluidic aerosol science
✓ Peer reviewed surface acoustic wave research
✓ Early mRNA LNP integrity work
✓ University of Melbourne Digital Simulation Lab usability testing
✓ Support from medtech and commercialisation programmes
✓ A growing IP position across core technology and device design
received positive feedback from caregivers and children, including preference over spacer use and confidence in home use.
This validation pathway matters because MISTI® is not being built as a single product story.
It is being built as a platform with clinical, commercial and therapeutic expansion potential.
Its broader opportunity is precision pulmonary delivery.
The same principles that support more usable inhaled therapy
today may also support future pathways across biologics, RNA based
therapies, public health deployment and strategic healthcare
partnerships.
It creates a scalable delivery platform with room to expand across
indications, formulations and care settings.
MISTI® is not just a better way to inhale medicine.
It is infrastructure for the future of medicine through the lungs.
MISTI® is building a mesh free, breath synchronised approach to more consistent
inhaled therapy and advanced therapeutic delivery.
If you are developing respiratory medicines, biologics, RNA based therapies or strategic
healthcare solutions, MISTI® offers a new pathway for pulmonary delivery.
Find answers about how MedMISTI™ works and what it can do for you
MISTI® is a mesh free pulmonary drug delivery technology that uses high frequency acoustic energy and breath actuation to generate controlled aerosol for inhaled therapy.
It is being developed to help medicine reach the lungs more reliably, while supporting treatment visibility through connected use data.
Traditional nebulisers may rely on jet, ultrasonic or mesh based aerosol generation. MISTI® uses high frequency acoustic energy without relying on a traditional mesh.
This mesh free approach is designed to reduce clogging risk, support controlled aerosol generation and create a more adaptable pathway for complex or sensitive formulations.
Mesh based systems can face challenges when drug flow is restricted, particles vary, or formulations are not well suited to the device.
By removing the mesh from the delivery equation, MISTI® is being developed to support more consistent aerosol generation and reduce the risk of delivery disruption linked to blockage.
Breath actuated delivery means the system is designed to detect when the patient begins to inhale and activate aerosol generation in response.
This helps align medicine delivery with the patient’s breathing pattern, rather than relying entirely on the patient to coordinate with the device.
Particle size helps determine where inhaled medicine travels in the respiratory system.
If particles are too large, they may deposit higher in the airway. Controlled micron sized aerosol particles are important for more targeted pulmonary delivery and may be especially valuable for advanced therapeutic applications.
MISTI® is being developed with future compatibility in mind, including potential use with biologics, RNA based therapies and other sensitive formulations.
Early technical work has shown promising results for biologic integrity, including in vitro work using lipid nanoparticle mRNA constructs.
MISTI® is designed to support connected treatment visibility. Depending on the application and development stage, the system may capture breath detection, actuation timing, device use, dose consistency and delivery related performance data.
This information may support adherence tracking, remote monitoring, clinical follow up and better treatment decisions.
MedMISTI™ is the first real world application of the MISTI® platform.
It has been designed for respiratory care patients who may need inhaled therapy to be more usable, more consistent and better aligned to real patient behaviour.
MISTI’s first application is focused on respiratory care. This may include patients who struggle with traditional inhalers, spacers or nebulisers, such as children, elderly patients, people living with asthma or COPD, neurodiverse patients and people with compromised breathing.
The broader platform is also relevant to pharmaceutical, biotech, healthcare and strategic partners exploring future pulmonary delivery pathways.
MISTI® is being developed as a pulmonary delivery platform, not just a single device.
MedMISTI™ is the first application, but the broader opportunity includes respiratory medicines, biologics, RNA based therapies, public health deployment and future strategic healthcare applications.
